Privately held molecular diagnostics company Diamir announced this week the publication of data by company researchers showing that two families of miRNAs can be used to detect mild cognitive impairment, a condition associated with the early stage of neurodegenerative disorders such as Alzheimer's disease.
According to the data, which appeared in Aging, members of the miR-132 and miR-134 families were detected in plasma and used to identify patients with mild cognitive impairment with an overall accuracy of 96 percent and 87 percent, respectively.
"We will focus on conducting larger studies and developing a test with the goal of making it available to the scientific and medical community as quickly as possible," Diamir CEO Kira Sheinerman said in a statement.